Livimax 300 US Pharma Treatment Treatment of primary cholestatic cirrhosis (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Ursodeoxycholic acid

Ingredient

Composition information	Content
Ursodeoxycholic acid	300mg

Uses

Indications

Livimax 300 is indicated in the treatment of primary bile cholecyst cirrhosis (PBC) and to dissolve cholesterol -rich cholesterol, no small to medium -sized contrast.

Ursodeoxycholic acid does not dissolve the cholesterol stones covered with calcium or stones with bile pigment components. Livimax 300 has a special position in the treatment of patients with surgical anti -surgery or desire to not surgery.

Children: Hepatic liver disorders are associated with cystic fibrosis in children from 6 to under 18 years old.

Pharmacokology

When used by oral, ursodeoxycholic acid reduces cholesterol in bile salts and reduces phospholipids in bile, thereby reducing the saturation of cholesterol saturated bile. The exact mechanism of effect of the drug has not been completely clarified.

Children with cystic fibrosis: from clinical reports with long -term experience for up to 10 years onwards about UCDA treatment in patients with cystic fibrosis related to bile disorders (CFAHD). There is evidence that the treatment of cystic fibrosis with UCDA may reduce the growth of bile ducts, prevent the progression of histological damage and recover changes to the liver if the drug is used in the early stages of CFAHD. The treatment with UDCA should be started right after being diagnosed with CFAHD to optimize the effectiveness of treatment.

Dynamic pharmacokinetics

Livimax 300 are indicated in the treatment of primary bile cholecyst cirrhosis (PBC) and to dissolve cholesterol -rich cholesterol, no small to medium -sized contrast.

Children: Hepatic liver disorders are associated with cystic fibrosis in children from 6 to under 18 years old.

Before taking Livimax 300 US Pharma Treatment Treatment of primary cholestatic cirrhosis (3 blisters x 10 tablets)

How to use

Take oral use.

Dosage

Livimax 300 is used by oral with a glass of water.

primary cholestatic cirrhosis

Adults and the elderly: 10-15mg Ursodeoxycholic acid (UDCA) for 1kg/ day and divided into 2-4 doses.

Children: Dosage related to weight.

Melt gallstones

Adults and the elderly: The usual dose is 6 - 12mg/kg/day, in the form of the only dose used at night or dividing the dose. Dosage may increase to 15mg/kg/day in obese patients, if necessary.

Treatment time may last up to 2 years, depending on the size of the gravel and should maintain the drug for another 3 months after the gravel disappears.

Children: Dosage related to weight.

Children from 6 to under 18 years old have cystic fibrosis: 20mg/kg/day divided into 2-3 doses, if necessary, the dose can be increased to 30mg/kg/day.

What to do when overdose? In general, other symptoms of overdose are not occurring because the absorption of ursodeoxycholic acid decreases when increasing the dose and thus being eliminated through feces.

Treatment: There is no specific treatment, symptomatic treatment of diarrhea by re -establishing water and electrolytes.

What to do when forgetting a dose?

Side Effects

Common, 1/10> ADR ≥ 1/100

Digestive: dung, diarrhea.

Very rare, 1/10000> ADR

Gastrointestinal: serious abdominal pain has occurred during the treatment of raw bile cirrhosis.

Bile liver: gallbladated gallstones can occur, making them unable to dissolve with bile acid therapy and patients need surgery. During the treatment of primary cholestatic cirrhosis in the progressive stage, the very rare cases of unsatisfactory cirrhosis are also reported, and will partially recover after stopping treatment.

Skin and subcutaneous tissue: urticaria.

unknown meetings

Skin and subcutaneous tissue: itching.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Livimax 300 Contraindicated in patients:

Hypersensitivity to bile acid or any component of the product. poor.

Caution when using

Ursodeoxycholic acid should be used under the supervision of health workers.

In the first 3 months of treatment, the parameters of liver function such as AST (SGOT), ALT (SGPT) and γ-AG need to be monitored every 4 weeks, then every 3 months. In addition to determining the response or non -response in patients treating primary cholestatic cirrhosis, the monitor also helps early detection of the risk of liver failure, especially in patients who are in the progressive stage of primary cholestatic cirrhosis.

When using the drug to dissolve cholesterol gallstones:

To assess the progress of treatment and timely determination of gallstones, depending on the size of the gravel, the gallbladder should be seen in general and see the clogged positions when the patient stands and lies on his back (ultrasound position) after 6-10 months of starting treatment (by X -ray of gallbladder with gallbladder medicine). If the gallbladder is not seen when taking X-rays, or calculating gallstones, gallbladder stenosis or often suffering from bile cramps, do not use Ursodeoxycholic acid.

When using the drug to treat the progression of primary cholestatic cirrhosis:

Rarely occurs unsatisfactory cirrhosis and patients have to stop treatment. If diarrhea occurs, the dose should be reduced and in case of previous diarrhea, the drug should not be used.

excipients:

The drug contains lactose excipients so it should not be used for galactose intolerance, lapp-lactase deficiency, glucose-galactose absorption disorders.

The effect of the drug on driving and operating machinery

The drug does not affect the ability to drive and operate machinery.

Use drugs for women during pregnancy and lactation

Use drugs for pregnant women:

There is no adequate data on the use of ursodeoxycholic acid, especially in the first three months of pregnancy. Animal studies have provided evidence of teratogenic effects in the early stages of pregnancy. Do not use ursodeoxycholic acid during pregnancy. Should stop treatment immediately if pregnant and consult a doctor.

Women who have the ability to have children should only be treated when they are using effective contraception: non -hormonal oral contraceptive methods are recommended by low -dose hormones. However, in patients using ursodeoxycholic acid to dissolve gallstones, should use contraception is not hormones, because hormonal contraceptives can increase gallstones. Need to avoid pregnancy before starting treatment.

Use drugs for breastfeeding women:

It is not known whether ursodexolic acid is excreted in breast milk. Therefore, ursodexolic acid should not be used during breastfeeding. If the treatment with ursodeoxycholic acid is necessary, it is necessary to stop breastfeeding.

Drug interaction

should not simultaneous Ursodeoxycholic acid with activated carbon, cholestyramin, colestipol or antacids containing aluminum hydroxyd and/ or smectit (aluminum oxyd), because these preparations can be associated with ursodexolic acid in the intestine and inhibit the absorption and effectiveness If you need to use preparations containing one of these substances, this product must be used at least 2 hours ago or after using ursodeoxycholic acid.

Ursodeoxycholic acid may increase the absorption of ciclosporin in the intestine. Ciclosporin concentration should be monitored when used simultaneously with ursodeoxycholic acid and adjust the dose of ciclosporin if needed.

In separate cases, ursodexolic acid can reduce the absorption of ciprofloxacin.

Ursodeoxycholic acid has been shown to reduce the peak concentration in plasma (CMAX) and the area under the curve (AUC) of nitrendipine. The drug can also interact, reducing the effectiveness of DASSON treatment. Combining observations with in vitro detections may show ursodeoxycholic acid that can cause cytochrom P450 3A enzyme induction. However, controlled clinical trials have shown that ursodeoxycholic acid has no effect that induces cytochrom P450 3A enzymes. Oral contraceptives, estrogen and hormones are estrogen and blood cholesterol drugs such as clofibrat may increase gallstones, reducing the effect of soluble gallstones of ursodeoxycholic acid.

The cavalry of the drug:

Due to the absence of studies on the correlation of the drug, not mixing this drug with other drugs.

Storage

Leave a cool place, avoid light, temperatures below 30⁰C.

To be out of reach of children, read the instructions carefully before use.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.